Our Take: Eli Lilly Stock Rises on China Weight-Loss Pill Approval
By Tech & Money Press · Our Take on Eli Lilly and the China obesity market · November 12, 2026
Eli Lilly (LLY) just beat its biggest rival to an important market. China approved orforglipron, Lilly’s GLP-1 weight-loss pill, making Lilly the first drugmaker to get a GLP-1 weight-loss pill cleared in the country, Reuters reported Thursday. The stock was trading at about $1,462.93 in premarket action at 8:08 a.m. ET, up about 1.8% from Wednesday’s close of $1,437.29, according to Webull data.
What happened
Until now, China had only approved GLP-1 drugs for weight management as injections, according to Reuters. Orforglipron, sold as Foundayo in the U.S. and the U.K., will compete with Lilly’s own weekly injection and with injections from Novo Nordisk, Pfizer and local company Innovent Biologics.
Novo has also applied to sell an oral version of Wegovy in China, as have Chinese drugmakers Jiangsu Hengrui Pharmaceuticals and Huadong Medicine with experimental pills, Reuters said. Lilly also told pharmaphorum that a separate application for orforglipron in type 2 diabetes is under review by China’s drug regulator.
Lilly didn’t say how it will price the drug in China or when it will be available, according to Reuters.
Why China matters
The opportunity is large but still early. Yang Huang, J.P. Morgan’s head of China healthcare research, has forecast that annual sales of GLP-1 weight-loss drugs in China could reach 30 billion yuan, or about $4.5 billion, within five to seven years, up from an estimated 3 billion to 4 billion yuan today, Reuters reported. China’s National Health Commission has said the share of people who are overweight or obese could top 65% by 2030, according to Investing.com.
A pill also solves a real problem. Lilly said in a statement, reported by pharmaphorum, that the way a drug is taken is “one of the important factors affecting adherence.” Many patients don’t want weekly shots, and a pill can be easier to start.
Lilly has been preparing for this. Earlier this year, it announced a $3 billion, 10-year investment in China to expand supply capacity, including plants in Suzhou and Beijing that will help supply orforglipron, pharmaphorum reported.
The catch
China is a self-pay market for these drugs. Weight-loss medicines aren’t covered by public health insurance and are almost never covered by private plans, so sales depend mostly on middle- and higher-income city residents, according to pharmaphorum. That makes price the key unknown. Local rivals with their own pills could also push prices down over time.
It’s also worth keeping the size in perspective. China made up about 3% of Lilly’s net sales, according to company data compiled by MarketScreener. Even a fast launch won’t change Lilly’s numbers overnight.
Our Take
We see this as a meaningful first-mover win, not a quick windfall. Being first with a pill in the world’s second-largest drug market gives Lilly time to win doctors and patients before Novo and local competitors arrive. In a category where Novo still leads in pills globally, according to pharmaphorum, that head start matters.
The stock already reflects a lot of good news. Lilly was up 33.7% this year through Wednesday’s close, compared with 11.3% for the S&P 500, Reuters reported, citing LSEG data. At about $1,462.93, the shares trade at roughly 47 times trailing earnings per share of $30.81, based on Webull data. Our view is that China is a long-term growth story for Lilly. The near-term moves will still depend more on U.S. demand for Zepbound, Mounjaro and Foundayo.
The details to follow are the launch date, the price, and whether Novo’s oral Wegovy gets cleared soon. We’d also follow the diabetes application, which would open a second use for the same pill.
The levels on the chart
- About $1,462.93: Thursday’s premarket price at 8:08 a.m. ET.
- $1,453: the 52-week high, set intraday on Nov. 5 (Webull).
- $1,333.22: the Nov. 6 low, the bottom of last week’s pullback.
- $1,136.66: the Oct. 2 low, where the stock was before its October rally.
Premarket prices are based on thin trading and can change before the 9:30 a.m. ET open.
Key takeaways
- China approved Lilly’s orforglipron, the first GLP-1 weight-loss pill cleared in the country (Reuters).
- LLY traded at about $1,462.93 premarket at 8:08 a.m. ET, up about 1.8% (Webull).
- J.P. Morgan sees China GLP-1 weight-loss sales reaching about $4.5 billion a year in five to seven years.
- Novo’s oral Wegovy is still awaiting approval in China.
- Price and launch timing are not yet known, and China is a self-pay market.
Disclaimer: For news and education only. Not financial advice. Tech & Money Press is not a registered investment advisor. Trading stocks involves risk, including the loss of your investment. Do your own research and consult a licensed professional before making any investment decisions.
Sources: Reuters via StreetInsider: Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China, Nov. 12, 2026. Investing.com: Eli Lilly stock rises after China approves weight-loss pill. pharmaphorum: Lilly beats Novo to China with an oral GLP-1 for obesity. Reuters via Boursorama (YTD performance, LSEG). MarketScreener: Eli Lilly company profile (sales by region). LLY daily prices, premarket quote (8:08 a.m. ET, Nov. 12), P/E and 52-week range: Webull.
Featured image: Photo: sergeitokmakov / Pixabay.